Results 51 to 60 of about 8,612,250 (158)

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition

Advanced Science, Volume 13, Issue 4, 19 January 2026.
This study presents YC3, a novel inhibitory TSHR‐targeting aptamer, as a promising therapeutic for Graves' ophthalmopathy (GO). YC3 suppresses pathological phenotypes in human orbital fibroblasts and improves outcomes in GO mice by binding to a previously unidentified allosteric site on TSHR, demonstrating the potential of aptamers in advancing ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Medical treatment for thyroid-associated ophthalmopathy

The medical management of thyroid-associated ophthalmopathy has been, and remains a clinical challenge. Several drugs have been used. Systemic steroids seem to be beneficial in patients with active disease.
Perros P; Kendall-Taylor P
core   +4 more sources

A Pruritic Predicament: An Unusual Presentation of Graves’ Disease Complicated by Pregnancy

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Pruritus is a known but uncommon symptom of hyperthyroidism that can be misinterpreted or overlooked in a patient presentation. This is a case report of a 40‐year‐old female who presents with a 3‐month history of severe, worsening pruritus. Further history demonstrated potential signs of hyperthyroidism, and laboratory values demonstrated low TSH ...
Rob Lawless, Evan Smith, Camryn Slone, Thaddeus Salmon, Semonti Nandi   +4 more
wiley   +1 more source

Exploring Thyrotoxic Hypercalcaemia Through Two Cases: A Myriad of Uncertainties

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Hypercalcaemia is a recognised complication of thyrotoxicosis usually related to increased bone resorption. However, coexistent hyperphosphataemia is uncommon and may create diagnostic uncertainty. It is postulated that serum calcium and phosphate levels rise due to high bone turnover and increased renal reabsorption of phosphate in response to excess ...
Don Asiri Abeysiriwardana, Pahala Gamage Nipuna Jeewantha Dias, Warsha Dilhani De Zoysa, Arosha Sampath Dissanayake, Kalyani Sen   +4 more
wiley   +1 more source

Lugol’s Iodine as a Key Treatment in Transient Gestational Thyrotoxicosis: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Introduction Transient gestational thyrotoxicosis (TGT) occurs when human chorionic gonadotropin (hCG) directly stimulates the maternal thyroid gland during the first trimester of pregnancy. We report a case of complicated TGT in a young woman who required treatment with Lugol’s solution.
Mariam Mabrouk, Najla Bchir, Dorra El Guiche, Anaam Ben Chehida, Emna Mraihi, Chadia Zouaoui, Haroun Ouertani, Mohammad Shahangir Biswas   +7 more
wiley   +1 more source

Thyroid-associated ophthalmopathy and TSH receptor autoantibodies in nonmetastatic thyroid cancer after total thyroidectomy.

, 2008
In a 58-year-old woman with nontoxic nodular goiter, a fine-needle aspiration biopsy showed the presence of papillary thyroid cancer, which was treated with total thyroidectomy in June 2000 and a subsequent ablative dose of 131-radioiodine. A posttherapy
Tolari S, ANTONELLI, ALESSANDRO, FERRANNINI, ELEUTERIO, Fallahi P, Ferrari SM   +4 more
core   +1 more source

Th1/Th2 Cytokines in Patients with Graves' Disease with or without Ophthalmopathy

Iranian Journal of Allergy, Asthma and Immunology, 2013
About 25-50% of Graves' disease (GD) patients develop thyroid eye diseases, which is associated with inflammatory process and abnormalities in the levels of several cytokines in orbital tissues in GD.
Fatemeh Esfahanian, Effat Naimi, Farideh Doroodgar, Zohre Jadali   +3 more
doaj  

Unilateral Graves’ Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report

Case Reports in Endocrinology, Volume 2026, Issue 1, 2026.
Background Tirzepatide is a dual agonist of the glucose‐dependent insulinotropic polypeptide (GIP) receptor and glucagon‐like peptide‐1 (GLP‐1) receptor, demonstrates significant efficacy in lowering blood glucose levels and reducing body weight. Consequently, its use has increased among patients with type 2 diabetes and obesity.
Yusuke Deto, Ryo Hasegawa, Shoya Ino, Satoru Shibata, Kouhei Ohno, Takahito Itoh, Tomoaki Matsumoto, Takayuki Miki, Kalyani Sen   +8 more
wiley   +1 more source